Author: backoffice

Kineret, a biologic drug, can prevent gout flare-ups

Kineret, a biologic drug, can prevent gout flare-ups

Gout is a prevalent type of auto-inflammatory arthritis that develops when MSU crystals accumulate in the synovial joints’ soft tissue. Acute gout flare-ups are marked by specific inflammatory symptoms such as pain, erythema, and edoema. They can lead to physical incapacity and a lowered quality of life. Therefore, one of the key objectives in treating […]
Read More
The management of Carbapenem-Resistant Acinetobacter baumannii Infections with Cefiderocol

The management of Carbapenem-Resistant Acinetobacter baumannii Infections with Cefiderocol

An opportunistic bacterial pathogen called Acinetobacter baumannii and it is predominantly linked to hospital infections. This new opportunistic infection has gained substantial notoriety because of a recent rise in occurrence. It is mostly attributed to sick combat forces returning from conflict zones, combined with a sharp rise in the incidence of multidrug-resistant strains. Acinetobacter baumannii […]
Read More
Anakinra's effectiveness in pericarditis: A systematic review

Anakinra’s effectiveness in pericarditis: A systematic review

Patient outcomes significantly improved as a result of anakinra. In addition, compared to conventional care, the pericarditis recovered more quickly and had a decreased risk of recurrence. Pericarditis, an inflammation of the pericardium, can cause severe chest pain and is likely to return despite therapy. An infection of the digestive or respiratory systems, pericarditis, can […]
Read More
The evolving role of Brentuximab Vedotin in classical Hodgkin Lymphoma

The evolving role of Brentuximab Vedotin in classical Hodgkin Lymphoma

With the introduction of Brentuximab Vedotin, a CD30-directed antibody-drug combination, the treatment strategy for people with classical Hodgkin lymphoma has changed. Since its first approval in 2011, BV has been thoroughly investigated in patients who had not previously received any treatment, relapsed, or were treated unsuccessfully. The antibody-drug conjugate’s indications for use in patients have […]
Read More
High Dose Anakinra shows promise in treating CRS

High-Dose Anakinra shows promise in treating CRS/ICANS Post CAR T-Cell Therapy

The possibility of the cutting-edge therapeutic approach known as chimeric antigen receptor (CAR) T-cell immunotherapy to treat a variety of resistant haematological malignancies has attracted attention. The serious side effects of CAR T-cell treatment continue to be of great concern. Early after CAR-T cell therapy, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are […]
Read More
Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma

Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma

An antibody-drug combination called Brentuximab Vedotin is commonly known as Adcetris. It may combine an anti-CD30 antibody with monomethyl auristatin E medication. It is an anti-neoplastic substance in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The first approval of brentuximab vedotin occurred in 2011. A boxed advice of progressive multifocal leukoencephalopathy […]
Read More
Adcetris and their Uses

Adcetris and their Uses

About Adcetris Brentuximab vedotin is the generic name of the Adcetris drug’s trade name. It is an antibody-drug recommended for a high form of lymphoma. It is a form of cancer that affects the body’s lymphatic system and certain white blood cells called lymphocytes. Administered through intravenous (IV) injection, this drug may sometimes be taken […]
Read More